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Background: Patients with COPD may share some clinical characteristics with asthma suf-
ferers. This phenotypic overlap between COPD and asthma is not yet well characterised.
Method: We have analysed data from the EPI-SCAN study, an epidemiological, population-
based study in Spain that included 3885 (40 to 80-year-old) subjects in order to investigate
the clinical and systemic inflammatory characteristics of COPD patients previously diagnosed
with asthma. Generic and COPD-specific quality of life, as well as physical activity, were also
assessed through standardised and validated questionnaires.
Results: A total of 385 (10.1%) subjects were diagnosed with COPD, 67 (17.4%) being classified
with the COPDeasthma overlap phenotype. Such patients were more likely to have dyspnea
and wheezing (p< 0.001 in both comparisons) and more frequent exacerbations (p< 0.001).Department, Hospital Universitari Vall d’Hebron, Pg Vall d’Hebron 119-129, 08035 Barcelona, Spain.
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@creal.cat (E. Duran-Tauleria), guadalupe.h.sanchez@gsk.com (G. Sa´nchez), vsobradillo@separ.es
Garcı´a-Rı´o).
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1054 M. Miravitlles et al.No differences in systemic inflammatory markers were observed except for lower NOx concen-
trations in overlap patients (pZ 0.013). This overlap phenotype significantly worsened specific
quality of life (11.1 units on the St. George’s Respiratory Questionnaire (SGRQ), 95%CI: 4.88
e17.36) and reduced physical activity (3.49 units on the London Chest Activities of Daily Living
(LCADL) scale, 95%CI: 1.06e5.94).
Conclusions: In this population-based study, 17.4% of the individuals identified with COPD had
an overlap COPDeasthma phenotype. This patient subgroup had more dyspnea, wheezing, ex-
acerbations, worse respiratory-specific quality of life, and reduced levels of physical activity.
Specific interventions may be required to adequately care for this subgroup of patients.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
The identification of chronic airflow limitation in an adult
patient may lead to a variety of diagnoses, with chronic
asthma and COPD among the most frequently made.1
Although asthma and COPD represent two distinct dis-
eases, with different pathogenesis and risk factors, they
share certain clinical characteristics that may overlap in
adult patients.2 Large population studies have revealed
that a high proportion of adult patients with respiratory
problems are commonly diagnosed with more than one
obstructive lung disease.3,4 Previous studies have shown
that the coexistence of asthma and COPD is associated with
more frequent utilisation of medical services and higher
overall costs.4 Moreover, follow-up data from the Third
National Health and Nutrition Examination Survey (NHANES
III) conducted in the US reported an increased mortality in
overlap patients compared with either asthma or COPD
alone.5
At an individual patient level, data from the COPDGene
study have demonstrated that 13% of subjects had overlap
COPD and asthma, with these individuals having an
increased frequency and severity of exacerbations, as well
as a more severely impaired health-related quality of life
(HRQoL), despite having similar FEV1 impairment and
reduced exposure to tobacco smoking compared with those
presenting only COPD.6
According to these results, such a COPDeasthma overlap
fulfils the criteria for receiving a new COPD phenotype
designation since these patients share certain clinical
characteristics and experience different outcomes.7,8
We analysed the data of the EPI-SCAN study9,10 to iden-
tify and characterise, for the first time, patients with the
overlap phenotype from an epidemiological, population-
based study and extend the knowledge about these pa-
tients with evaluation of the physical activity and factors
related to their health-related quality of life (HRQoL).Methods
Complete details of themethodology and a full description of
theparticipation rates and sample characteristics used in the
EPI-SCAN study have already been published.10 Briefly, this
was a multicenter, cross-sectional, population-based study
conducted at 11 sites throughout Spain.9 The final population
consisted of 4274 non-institutionalized participants, 40e80-years-old. The study was approved by the corresponding
ethics committees and written informed consent was ob-
tained from all participants.
COPD was defined by a post-bronchodilator FEV1/FVC
ratio of <0.70. All participants with spirometric-defined
COPD were classified as overlap COPDeasthma subjects if
they answered affirmatively that they had been previously
diagnosed with asthma.6
Procedures
Baseline dyspnea was assessed using the Modified Medical
Research Council (mMRC) scale,11 with subjects completing
the European Commission for Steel and Coal (ECSC) ques-
tionnaire on respiratory symptoms,12 the Spanish version of
the London Chest Activities of Daily Living (LCADL) scale.13
Health-related quality of life (HRQoL) was assessed with
one generic questionnaire, the EuroQoL five-Dimension
(EQ-5D) questionnaire,14 and the respiratory-specific St.
George’s Respiratory Questionnaire (SGRQ).15 Comorbid-
ities were assessed with the Charlson comorbidity index.
Lung function tests and a 6-min walking test were per-
formed at each site using the same equipment according to
the current recommendations, as previously described.9,10
In brief, spirometric parameters were obtained at each
site using the same equipment, a Master Scope CT version
5.2 (VIASYS Healthcare, Hoechberg, Germany). Lung func-
tion was measured before and then 15e30 min after inha-
lation of 200 mg of salbutamol. A bronchodilator test was
considered positive when there was an increase in FEV1
(mL) post-bronchodilator >12% and >200 mL.
Blood samples were collected using standardized pro-
cedures and stored at 80 C for biomarker analysis, as
previously described.16 The biomarkers analysed were TNF-
a, interleukin (IL)-6, IL-8, C-reactive protein (CRP), alpha-1
antitrypsin (A1AT), nitrites/nitrates (NOx), albumin, and
fibrinogen. Exclusion criteria for biomarker analysis
included a previous diagnosis of acute myocardial infarc-
tion, angina, congestive heart failure, cancer, hepatic
cirrhosis, chronic renal failure, rheumatoid arthritis, or any
other systemic inflammatory disease.
Statistical analysis
Values are expressed as the mean and standard deviation or
percentage. Differences between groups were analysed
using the chi-square or Student’s t tests, as appropriate.
AsthmaeCOPD phenotype 1055Multiple linear regression analyses were used to identify
the variables associated with the scores obtained from the
LCADL, EQ-5D and SGRQ questionnaires. The results
represent the adjusted standardised beta coefficients and
their 95% confidence intervals (95% CI), which provide a
measure of the modification of each of the scores as eval-
uated by every unit of change of the relevant explanatory
variable in the model. Analyses were performed using the
SPSS statistical package version 18. A p value< 0.05 was
considered significant.
Results
Population characteristics
Interviews were completed for 3885 subjects of a total of
4274 eligible individuals, and spirometry was performed in
3802 subjects. There were 385 (10.1%) subjects with post-
bronchodilator FEV1/FVC< 0.7.
Sixty-seven (17.4%) subjects presented the overlap
COPDeasthma phenotype. A descriptive analysis of COPD
subjects, either by the presence or absence of this overlap
phenotype, is presented in Table 1. Subjects with overlap
COPDeasthma were more likely to be: women, had never
smoked, with a high BMI, but presenting a similar degree of
severity in terms of spirometry and the 6-minute walkingTable 1 Demographic, clinical and functional characteristics
COPDeasthma phenotype.
All COPD (nZ 385) Overl
Gender, men (%) 271 (70.4) 30
Age, years 64 (10.1) 63.8
BMI, kg/m2 28 (4.8) 29.1
Smoking history, %
Smoker 34.3 16.4
Ex-smoker 39.7 26.9
Never smoked 26.0 56.7
Pack-years 41.5 (26.2) 27.5
Lung function pre-bronchodilator
FVC, mL 3328 (1031) 3014
FVC, % 83.2 (18.8) 82.2
FEV1, mL 2046 (688) 1795
FEV1, % 70.6 (18.2) 67.6
FEV1/FVC 61.6 (8.5) 59.9
Lung function post- bronchodilator
FVC, mL 3518 (1037) 3195
FVC, % 87.9 (18.6) 86.9
FEV1, mL 2182 (705) 1945
FEV1, % 75.1 (18) 72.7
FEV1/FVC 61.9 (7.2) 60.6
Reversibility
Positive BDT, % 24.6 28.8
Increase in FEV1, ml 135 (215) 149
6MWT, m. 441 (120.9) 436.2
mMRC Dyspnea score 1.64 (0.86) 1.9
Charlson index 0.98 (1.04) 1.44
BMI: body mass index; BDT: bronchodilator test; and 6MWT: 6-minutetest. They also had a higher Charlson comorbity index;
however, when comorbidities were considered individually,
only diabetes was somewhat more frequent (albeit not
significantly) in overlap patients (14.9% versus 10.6%;
pZ 0.32). There were no differences in the prevalence of
cough and sputum production, but patients with the over-
lap phenotype were more likely to have dyspnea and
wheezing (Fig. 1). Fig. 2 shows the proportion of COPD
subjects with exacerbations within the past year, as well as
those with overlap COPDeasthma status.
Serum biomarkers
A total of 310 subjects fulfilledall criteria andprovidedablood
sample for analysis (48 with the overlap phenotype). There
were no significant differences in the blood concentrations of
the biomarkers measured in either group of patients, except
for NOx, the concentrations of which were significantly lower
in patients with the overlap phenotype (Table 2).
Impact of the overlap phenotype on daily living
activities and HRQoL
Patients with the overlap phenotype had more difficulties
in their daily living activities, particularly in the domestic
and leisure domains. They exhibited a significantlyof participants with COPD and with or without overlap
ap (nZ 67) Non-overlap (nZ 318) P value
(44.8) 241 (75.8) <0.001
(11.4) 64.1 (9.9) 0.83
(4.5) 27.8 (4.8) 0.045
38.1 <0.001
42.5
19.5
(20.4) 43.1 (26.4) 0.002
(1105) 3393 (1005) 0.007
(18.2) 83.3 (19) 0.64
(672) 2098 (682) 0.001
(16.4) 71.2 (18.6) 0.15
(7.7) 61.9 (8.7) 0.08
(1193) 3584 (992) 0.006
(19.8) 88.1 (18.3) 0.63
(772) 2230 (682) 0.003
(17.7) 75.6 (18.1) 0.22
(7.1) 62.1 (7.2) 0.12
23.7 0.38
(294) 132 (195) 0.65
(140.4) 441.9 (117.2) 0.76
(0.83) 1.59 (0.85) 0.008
(0.78) 0.89 (1.07) <0.001
walking test.
Table 2 Serum biomarkers of patients with and without
the overlap COPDeasthma phenotype.
All COPD
(nZ 310)
Overlap
(nZ 48)
Non-overlap
(nZ 262)
P value
Albumin
(g/L)
45.3 (2.8) 45 (2.4) 45.4 (2.9) 0.37
Alpha-1
antitrypsin
(mg/dL)
155.2
(44.2)
155.4
(44.2)
155.1
(44.3)
0.97
Fibrinogen
(g/L)
3.54 (1.1) 3.35 (1.1) 3.57 (1.1) 0.18
C-reactive
protein
(mg/dL)
0.55 (0.92) 0.49 (0.68) 0.56 (0.96) 0.66
TNF-a (pg/mL) 13.4 (10.6) 13.2 (7.5) 13.4 (11.1) 0.89
IL-6 (pg/mL) 4.79 (6.4) 5.34 (6) 4.68 (6.5) 0.52
IL-8 (pg/mL) 7.41 (12) 7.58 (15.1) 7.39 (11.4) 0.92
NOx (nmol/L) 30.7 (21.9) 24.7 (14.7) 31.6 (22.7) 0.013
TNF-a: tumour necrosis factor alpha; IL: interleukin; NOx: ni-
trites/nitrates.
Fig. 1 Prevalence of respiratory symptoms in patients with
or without the overlap COPDeasthma phenotype. *p< 0.001.
Table 3 Physical activity and health-related quality of
life of patients with and without the overlap COPDeasthma
phenotype.
All COPD
(nZ 385)
Overlap
(nZ 67)
Non-overlap
(nZ 318)
P value
LCADL
Total 16.6 (6.3) 19.1 (8.3) 16.1 (5.8) 0.002
Self-care 4.7 (1.5) 5.0 (2.0) 4.6 (1.4) 0.054
Domestic 5.5 (3.9) 6.9 (4.6) 5.3 (3.7) 0.003
Physical 3.1 (1.4) 3.5 (1.7) 3.1 (1.3) 0.051
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the SGRQ (31.1 units (SDZ 20.2) compared with 19.4
(SDZ 17.4; p< 0.001)) and the generic HRQoL as measured
by the EQ-5D index score (Table 3).
Three different multivariate models were constructed to
evaluate the impact of the overlap phenotype on activities
of daily living (the LCADL questionnaire), and the generic
(EQ-5D) and specific (SGRQ) HRQoL scores. The first model
demonstrated the independent relationship of the overlap
phenotype with the activity scores, with an impairment of
3.49 (95% CIZ 1.06e5.94; p< 0.001) units in the LCADL.
Other variables associated with poorer activity scores were
a low post-bronchodilator FEV1 score (%), female sex, and a
worse Charlson index (Table 4).
Regarding specific HRQoL, the overlap phenotype had a
high impact, with an independent contribution of 11.12
(95% CIZ 4.88e17.36; p< 0.001) units in the SGRQ. Other
variables significantly and independently associated with
poor SGRQ scores were, again, a low post-bronchodilator
score FEV1 (%) and Charlson index, female sex, and higher
smoking consumption in terms of pack-years (Table 4). In
contrast, there was no significant association of the overlap
phenotype with generic HRQoL. The variables significantly
associated with poorer generic HRQoL scores were: a low
post-bronchodilator FEV1 score, a higher Charlson comor-
bidity index, and female sex (Table 4).
Discussion
Patients identified as having the COPDeasthma overlap
phenotype had more dyspnea and wheezing, moreFig. 2 Frequency of exacerbations during the previous year
in patients with or without the overlap COPDeasthma pheno-
type. *p< 0.001.comorbidities, and more frequent exacerbations, despite
being of similar age and having comparable FEV1 values (%
predicted) and considerably less exposure to smoking. We
could not find any differential pattern of systemic inflam-
mation between COPD patients with or without the overlap
phenotype, but the latter was associated with significantly
reduced physical activity and worse respiratory-specific
HRQoL.
To our knowledge, this is the first population-based
study that has attempted to identify and characterise COPD
patients with mixed disease, in contrast to previous studiesLeisure 3.3 (0.9) 3.5 (1.2) 3.2 (0.9) 0.043
EQ-5D
Utility score 0.81 (0.19) 0.76 (0.19) 0.82 (0.19) 0.037
VAS score 70.8 (16.9) 66.9 (14.8) 71.5 (17.2) 0.067
SGRQ 21.2 (18.3) 31.1 (20.2) 19.4 (17.4) <0.001
Global 26.8 (22.1) 37.3 (22.5) 24.9 (21.5) <0.001
Symptoms
Activity 29.7 (25.5) 41.3 (27.2) 27.6 (24.7) <0.001
Impact 14.1 (16.8) 23.1 (20.2) 12.4 (15.6) <0.001
LCADL: London Chest Activity of Daily Living scale; EQ-5D: Euro
Quality of Life 5-Dimensions questionnaire; VAS: Visual
Analogue Scale; and SGRQ: Saint George’s Respiratory Ques-
tionnaire.
Table 4 Multiple regression analysis of variables associ-
ated with LCADL, EQ-5D, and SGRQ scores.
Variable B 95% CI P value
LCADL
Constant 15.92 8.48 to 23.27 <0.001
Overlap phenotype 3.49 1.06 to 5.94 0.005
Post-bronchodilator
FEV1(%)
0.067 0.11 to e0.021 0.004
Charlson index 2.02 0.52 to 3.53 0.008
Gender (female) 3.87 1.86 to 5.87 <0.001
Age 0.014 0.092 to 0.064 0.72
Pack-years 0.011 0.018 to 0.040 0.46
EQ-5D score
Constant 0.657 0.46 to 0.86 <0.001
Overlap phenotype 0.033 0.098 to 0.033 0.32
Post-bronchodilator
FEV1(%)
0.003 0.001 to 0.004 <0.001
Charlson index 0.079 0.120 to 0.039 <0.001
Gender (female) 0.062 0.116 to 0.008 0.025
Age 0.001 0.001 to 0.003 0.25
Pack-years 0.0001 0.001 to 0.001 0.96
SGRQ
Constant 45.71 26.68 to 64.75 <0.001
Overlap phenotype 11.12 4.88 to 17.36 0.001
Post-bronchodilator
FEV1(%)
0.48 0.59 to 0.36 <0.001
Charlson index 6.51 2.67 to 10.35 0.001
Gender (female) 7.09 1.97 to 12.23 0.007
Pack-years 0.10 0.025 to 0.17 0.009
Age 0.99 0.29 to 0.10 0.33
LCADL: London Chest Activity of Daily Living scale; EQ-5D: Euro
Quality of Life 5-Dimensions questionnaire; and SGRQ: Saint
George’s respiratory questionnaire.
AsthmaeCOPD phenotype 1057derived from COPD cohorts. Interestingly, the prevalence
observed in our study (17.4%) was very similar to that
observed in the COPDGene cohort that used the same
definition of overlap phenotype, albeit from a group of
previously diagnosed COPD patients (13%),6 and it is nearly
coincident with the 19% of subjects that general practi-
tioners could not clearly classify as either COPD or asthma
in their routine practice because these patients shared
characteristics of both diseases.17 The prevalence of this
overlap phenotype may increase with age.2,3
There is controversy about the designation of patients
that share clinical characteristics of COPD and asthma.1,2,18
The definition used in our study has been adopted from the
COPDGene cohort6 and is useful for epidemiologic research.
It corresponds to adult subjects who were diagnosed with
asthma before the age of 40 and who currently present a
post-bronchodilator FEV1/FVC< 0.7. Although they could
also be classified as chronic irreversible asthmatics,19 at the
same time they perfectly match the current criteria for
COPD, which does not exclude non-smokers or subjects
with a previous diagnosis of asthma.20 In fact, previous or
active asthma is a risk factor for the development of fixed
airflow obstruction,21 while cigarette smoking is the main
risk factor for the development of persistent airflowlimitation in asthmatics.22 Therefore, a subgroup of in-
dividuals diagnosed with COPD was, in fact, asthmatics that
had developed a fixed airflow obstruction and who could
have been labelled as COPD according to the current defi-
nition of the disease.23
The proper diagnosis of this overlap phenotype may be
particularly relevant if such subjects present differential
clinical or inflammatory characteristics, a different prog-
nosis and/or a different response to treatment.8 Previous
studies have shown that some of these individuals present a
more eosinophilic bronchial inflammation24,25 that responds
better to inhaled corticosteroids.25e28 Such treatment has
been incorporated into several management guidelines for
COPD and recommends early introduction of inhaled corti-
costeroids in patients with COPD and coexisting asthma (or
overlap phenotype).29e31 To avoid excessive and inade-
quate use of inhaled corticosteroids in early COPD, one
expert group has developed criteria for the diagnosis of this
overlap phenotype,32 although final validation of these
criteria is still lacking. We were, unfortunately, not able to
study bronchial inflammation in our population and neither
could we discern any particular pattern of systemic
inflammation in our subgroup of overlap patients compared
with the rest of the COPD subjects. The only exception to
this was the observed decrease in NOx, which is difficult to
interpret as an isolated finding because of its large vari-
ability, although it might indicate decreased oxidant ac-
tivity compared with COPD, albeit without coexisting
asthma.
The characteristics observed in our population were
similar to those described in the COPDGene study,6 which
included a similar FEV1 (% predicted) and exercise capacity,
as measured by the 6-minute walking test, but significantly
more frequent exacerbations and worse HRQoL as
measured by the SGRQ, in contrast with a lower exposure to
smoking. In addition, our population was predominantly
female, and had both more comorbidities and a higher
prevalence of respiratory symptoms, particularly wheezing
and dyspnea. Conversely, the overlap phenotype was not
associated with an increased prevalence of coughing,
sputum production or positive bronchodilator test. The
same results with the BDT were observed in the COPDGene
cohort.6 It is possible that the dose of 2 puffs of salbutamol
(or albuterol) used in both studies may have reduced the
possible number of reversible patients, and differences
between the overlap and non-overlap patients in frequency
of positive BDT could have emerged. Regarding prognosis,
our overlap patients reported more frequent exacerbations
in the previous year compared with the COPDGene cohort.6
Other studies have observed that patients with coexisting
asthma and COPD have a higher risk of death during follow-
up compared with those with either asthma or COPD alone.5
These results indicate the importance of proper diagnosis
and management of this particular subset of mixed-disease
patients.
To the best of our knowledge, this is the first study to
examine physical activity in patients with the overlap
COPDeasthma phenotype. Reduced physical activity is a
well-recognised prognostic factor for admission and mor-
tality in COPD patients.33,34 Those with the overlap
phenotype in our own study exhibited significantly reduced
physical activity, despite a similar exercise capacity as
1058 M. Miravitlles et al.measured by the 6-mile walking test. In fact, the overlap
phenotype was significantly and independently associated
with reduced activity in the multivariate model, as it was
with female sex, a higher number of comorbidities, and a
lower FEV1 value (% predicted).
Respiratory-specific HRQoL, as measured by the SGRQ,
was significantly impaired in overlap patients in the
COPDGene cohort.6 Similarly, Kauppi et al.35 found that
coexisting asthma and COPD was associated with worse
HRQoL than asthma or COPD alone. We have extended this
finding by analysing the independent contribution of the
overlap phenotype to the SGRQ score. In our population, the
overlap phenotype explained an 11-unit increase (wors-
ening) of the SGRQ score and had the highest impact among
the selected variables, followed by female sex (7.09 units),
Charlson index (6.51 units), post-bronchodilator FEV1 (%
predicted) (0.48 units), and pack-years of smoking (0.10
units). This is a relevant finding, since an increase in 4 units
in the SGRQ total score has been associated with a 5% in-
crease in the overall risk of mortality and a 13% increase in
respiratory mortality.36 It is likely that the increasing
symptomatology and the increasing frequency of exacer-
bations reported by overlap patients account, at least in
part, for the impact of this phenotype on physical activity
and HRQoL. Another unique observation in our study is the
lack of any association between the overlap phenotype and
the generic HRQoL as measured by the EQ-5D. The generic
EQ-5D questionnaire has been shown to differentiate be-
tween COPD severity stages,10,37 with scores proving
significantly worse in female patients with COPD,38 as well
as in those of lower socioeconomic classes.39 Moreover, it is
a good predictor of exacerbations and of the poor evolution
of exacerbations.40 In concordance with these results, we
observed that the poorer EQ-5D utility scores in our patients
strongly correlated with female sex, impaired FEV1 (% pre-
dicted), and more comorbidities.
In summary, there are a significant number of COPD
patients (between 15% and 20%) with concomitant
asthma.2,6,17,25,35 These patients fulfil all of the criteria
warranting designation of a new COPD phenotype7,8:
increased symptomatology and more frequent exacerba-
tions,6 different inflammatory patterns with a predomi-
nance of eosinophilic inflammation,24,25 increased response
to oral41 and inhaled corticosteroids,25e28 reduced physical
activity and impaired disease-specific HRQoL,35 and
reduced survival.5 Clear diagnostic criteria and manage-
ment guidelines for this phenotype must be developed and
prospectively validated, and this phenotype should be
incorporated in phenotype-guided management of COPD.42Acknowledgement
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